Founded in 1974, the University of Vermont Cancer Center is Vermont’s only not-for-profit comprehensive clinical and research cancer center.
Hello From Vermont
Over the past year, the University of Vermont Cancer Center has continued its steady progress towards National Cancer Institute re-designation. While that goal guides our efforts, it is the steady, daily practice of improving what we do that is shaping our cancer center in lasting ways.
This journey has required clearer communication, stronger scientific collaboration, and a more deliberate alignment across our programs. The process has made us more focused, more connected, and more confident in our shared mission.
We also continue to see the impact of this growth reflected in our communities. Whether through expanded participation in clinical trials, outreach in rural areas, or research partnerships that address the needs of Vermonters and northern New Yorkers, the work we’re doing is reaching the people who rely on us most.
The stories in this report offer a glimpse into our momentum. They highlight scientific breakthroughs, expanded training opportunities, community-engaged research, and patients whose experiences inspire us to keep moving forward. Together, they show a center evolving with purpose and growing in ways that strengthen our mission. As we continue our steady march toward National Cancer Institute re‑designation, we look forward to deepening our impact across our catchment area.
Randall F. Holcombe, M.D., M.B.A. J. Walter Juckett Chair in Cancer Research Director, University of Vermont Cancer Center Associate Dean for Cancer Programs, UVM Larner College of Medicine
Pictured: The launch of UVM Cancer Center's Outreach and Education van with BioMobile Discovery Lab at the Vermont State Capitol on May 1, 2025.
By the Numbers
in total grant funding
Members
Active research grants
Staff members
Departments represented
UVM colleges represented
Grant Spotlights
Sylvie Doublié, Ph.D., is part of a multi-institutional team that received an NCI grant, for which she serves as director of the protein expression and purification core. Dr. Doublié also leads a project to study the molecular mechanisms of human DNA polymerase theta.
Nancy Gell Ph.D., MPH, received a grant from the National Institute for Occupational Safety and Health to pilot a tele-exercise program for World Trade Center responders, a population experiencing higher rates of an aggressive form of prostate cancer.
Elias Klemperer, Ph.D., received a grant from NCI to study how to catalyze cigarette smoking cessation through harm reduction among people who are unmotivated to quit.
Scott Langevin, Ph.D., MHA, will study circular RNA in malignant pleural mesothelioma and plasma extracellular vesicles through a grant from the Mesothelioma Applied Research Foundation.